Artículos por temáticas

Carbon-based nanotechnology for Parkinson's disease: diagnostic and therapeutic innovations

Lafi Z, Asha S, Asha SY.

Nanomedicine (Lond). 2025 Aug;20(16):2023-2041. doi: 10.1080/17435889.2025.2535940. Epub 2025 Jul 23.

Addressing Variability and Bridging the Gap in Parkinson's Disease Care: A Call to Action

Di Luca DG, Shalash A.

Mov Disord Clin Pract. 2025 Jul 22. doi: 10.1002/mdc3.70255. Online ahead of print.

Social Cognition in Neurodegenerative Disorders

Shim Y, Na S, Yang SJ, Ryu HJ, Yoon B, Rhee HY, Jang JW, Jung YH, Chin J.

Dement Neurocogn Disord. 2025 Jul;24(3):147-161. doi: 10.12779/dnd.2025.24.3.147. Epub 2025 Jul 7.

Association between dapagliflozin and risk of dementia and Parkinson's disease: a subgroup analysis of a meta-analysis of randomized controlled trials

Fernandes JV, Ramos JV, Holanda MM.

Minerva Med. 2025 Aug;116(4):323-328. doi: 10.23736/S0026-4806.25.09695-8. Epub 2025 Mar 27.

Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations

Biundo R, Bezdicek O, Cammisuli DM, Cholerton B, Dalrymple-Alford JC, Edelstyn N, Fiorenzato E, Holker E, Martinez-Horta S, Martini A, Santangelo G, Segura B, Siri C, Tröster A, Mestre TA, Ferro ÁS, H

Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30293. Online ahead of print.

Cognition and obstructive sleep apnea in Parkinson's disease: randomized controlled trial of positive airway pressure

Lajoie AC, Lafontaine AL, Kimoff RJ, Benedetti A, Robinson AR, Létourneau M, Crane J, Scanga A, Noel F, Kaminska M.

Sleep. 2025 Jul 11;48(7):zsaf038. doi: 10.1093/sleep/zsaf038.

Capturing α-synuclein aggregation interactors using UltraID-LIPA

Reddy K, Dieriks BV.

Trends Neurosci. 2025 Aug;48(8):557-559. doi: 10.1016/j.tins.2025.07.002. Epub 2025 Jul 10.

Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder

Joza S, Delva A, Tremblay C, Vo A, Filiatrault M, Tweedale M, Gagnon JF, Postuma RB, Dagher A, Klein J, Hu M, Dusek P, Marecek S, Varga Z, Taylor JP, O'Brien JT, Firbank M, Thomas A, Donaghy PC, Lehér

EBioMedicine. 2025 Jul;117:105753. doi: 10.1016/j.ebiom.2025.105753. Epub 2025 May 29.

The quest for Parkinson's disease biomarkers: traditional and emerging multi-omics approaches

Sharma P, Dhamija RK.

Mol Biol Rep. 2025 Aug 16;52(1):831. doi: 10.1007/s11033-025-10929-x.

Neurophysiology of Atypical Parkinsonian Syndromes: A Study Group Position Paper

Suppa A, Asci F, Kamble N, Chen KH, Sciacca G, Merchant SHI, Tijssen MAJ, Chen R, Hallett M, Pal PK.

Mov Disord. 2025 Aug;40(8):1451-1510. doi: 10.1002/mds.30225. Epub 2025 May 12.

Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges

Almasi F, Abbasloo F, Soltani N, Dehbozorgi M, Moghadam Fard A, Kiani A, Ghasemzadeh N, Mesgari H, Zadeh Hosseingholi E, Payandeh Z, Rahmanpour P.

Mol Neurobiol. 2025 Jul;62(7):8381-8399. doi: 10.1007/s12035-025-04788-7. Epub 2025 Feb 25.

Protein and RNA chaperones

Sahoo BR, Bardwell JC.

Mol Aspects Med. 2025 Aug;104:101384. doi: 10.1016/j.mam.2025.101384. Epub 2025 Jul 14.

Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from early-onset Parkinson's disease to perinatal lethality and disrupt mitochondrial function

Magrinelli F, Tesson C, Angelova PR, Rodriguez JA, Scardamaglia A, O'Callaghan B, Lowe SA, Salazar-Villacorta A, Chung BH, Jaconelli M, Vona B, Esteras N, Mammana A, Shimazu J, Kwong AK, Courtin T, Al

medRxiv [Preprint]. 2025 Jul 21:2024.06.19.24308302. doi: 10.1101/2024.06.19.24308302.

Molecular Function of Midnolin and Its Relevance to Parkinson's Disease

Obara Y, Chiba A.

Mol Cell Biol. 2025 Jul 22:1-10. doi: 10.1080/10985549.2025.2535666. Online ahead of print.

Targeting the redox neuroinflammatory nexus: insights into Alzheimer's and Parkinson's diseases

Dharshini LCP, Sakthivel KM, Rex KGR, Rasmi RR.

Inflammopharmacology. 2025 Jul;33(7):3885-3895. doi: 10.1007/s10787-025-01831-w. Epub 2025 Jul 2.